Ribavirin for RSV lower respiratory tract infection

Journal of Family Practice

Volumn 43, Issue 6, 1996, Pages 536-537

  Zamorski, Mark ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

AEROSOL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; INFANT; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RESPIRATORY TRACT INFECTION; RISK; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION;

AEROSOLS; ANTIVIRAL AGENTS; HUMANS; INFANT; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RIBAVIRIN; RISK; TREATMENT OUTCOME;

EID: 0030346877     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. American Academy of Pediatrics, Committee on Infectious Diseases. Use of ribvirin in the treatment of respiratory syncitial virus infection. Pediatrics 1993; 92:5014.
2. American Academy of Pediatrics, Committee on Infectious Disease. Reassessment of the indications for ribavirin therapy in respiratory syncitial virus infections. Pediatrics 1996; 97:137-40.
3. Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncitial virus infections. J Clin Epidemiol 1996; 49:963-7.
4. Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in respiratory syncitial virus infection. Pediatr Infect Dis J 1993; 12:209-13.